查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1857756

按检测类型、应用领域和最终用户分類的微量残存疾病检测市场 - 全球预测 2025-2032

Minimal Residual Disease Testing Market by Test Type, Application Areas, End-User Vertical - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，微量残存疾病检测市场规模将达到 44.7 亿美元，复合年增长率为 11.47%。

关键市场统计数据
基准年 2024 18.7亿美元
预计年份：2025年 20.8亿美元
预测年份 2032 44.7亿美元
复合年增长率 (%) 11.47%

微量残存疾病（MRD）检测已从一项专门的研究性检测发展成为一项重要的临床工具，它能够为血液肿瘤和固态肿瘤的预后评估、治疗强度指导以及适应性治疗策略的製定提供资讯。临床医生和实验室负责人现在不仅将MRD视为一种生物标记物，更将其视为一种决策工具，它影响着缓解评估、復发监测以及新治疗方法的合格。因此，诊断实践正在采用更广泛的分析方法、更高的灵敏度阈值以及旨在将检测结果整合到快速变化的临床路径中的工作流程。

更灵敏的检测平台的引入以及临床试验终点与微小残留病（MRD）状态的一致性正在加速MRD检测的临床应用，同时，样本处理、品管和报告标准的同步进步也开始降低实验室间的差异。因此，MRD检测正处于临床紧迫性和技术创新的交汇点：它必须在影响治疗方法选择的时间范围内提供可重复的、具有临床意义的结果。因此，对于那些希望将MRD检测从专科中心推广到常规实践的相关人员，了解分析能力、临床验证和操作准备之间的相互作用至关重要。

分析创新、临床检验以及与治疗决策框架的整合将推动微小残留病灶检测发生变革性转变。

随着高灵敏度分子技术、纯化细胞检测和数位分析的融合，微小残留疾病（MRD）检测领域正经历变革性的转变。针对低等位基因频率检测的标靶化次世代定序仪panel、可实现绝对定量分析的数位PCR方法以及针对标准化免疫表型分析优化的多参数流式细胞技术创新技术，共同提高了MRD的检测标准。同时，改进的检体储存方法、集中式参考检测以及跨平台检验研究正在降低实验室间差异，并增强临床医生对MRD检测结果的信心。

除了分析技术的进步，将微小残留病灶（MRD）纳入临床试验设计和监管路径正在重塑商业性和临床奖励，从实验室资讯系统到基于云端基础的变异解读等数位化基础设施，支援更快的结果交付和互联分析，从而实现可扩展的临床决策支援。这些转变正在加速MRD从一种小众诊断方法转向精准肿瘤学工作流程中标准化要素的转变。

评估美国2025年关税政策调整对供应链成本结构及临床取得微小残留疾病诊断的累积影响

2025年生效的关税调整为依赖全球一体化供应链获取仪器、试剂和耗材的相关人员带来了新的营运复杂性。进口专用设备和检测组件的关税提高将增加单位成本，并促使奖励调整筹资策略。对于临床实验室和诊断试剂生产商而言，这些成本压力可能导致净利率下降、高成本设备的更新换代週期延长，以及需要重新评估定价和服务模式以在不影响临床应用的前提下维持生存。

除了直接的成本影响外，关税还会造成供应链摩擦，延长关键试剂和备件的前置作业时间。延长的补货週期将加剧高通量检测中心的库存风险，迫使实验室实现供应商多元化，或对依赖在地采购原料的替代检测方法合格。政策应对措施和商业性缓解措施正在陆续出台。一些机构正在加快对区域製造的投资，而另一些机构则在协商长期供应协议以分散关税风险。同时，资源有限的医院和诊断网路可能面临先进微生物鑑定平台的延迟或取得受限。因此，相关人员在预测技术采用时间表和设计稳健的营运模式时，必须考虑关税引起的成本和可用性变化。

关键细分洞察揭示了检测方式的临床应用和最终用户垂直领域如何共同决定其采用优先顺序和价值创造。

从细分观点出发，我们可以看到分析方法、临床适应症和最终用户类型如何相互作用，从而影响微小残留疾病（MRD）检测的普及路径和价值创造。染色体微阵列细胞遗传学和萤光原位杂交（FISH）等检测方法在某些血液学领域发挥着重要的结构异常检测作用，它们与流式细胞流式细胞技术方法并存，其中多参数和单参数平台提供了互补的细胞分辨率。分子检测方法占据核心地位。标靶化次世代定序仪panel和全基因组定序为基于突变的MRD评估提供了灵敏度和广度，而数位PCR和定量PCR则可快速、经济高效地对预定义标靶进行定量。

应用领域进一步决定了哪些技术方案应优先考虑。白血病亚型，包括急性淋巴性白血病、急性骨髓性白血病和慢性淋巴性白血病，均采用分子检测和免疫表型检测来正交确认缓解状态。淋巴瘤检测涵何杰金氏病和非何杰金氏病淋巴瘤，需要客製化的检测设计，以平衡灵敏度和肿瘤异质性。多发性骨髓瘤和某些固态瘤，例如乳癌和大肠癌，需要客製化的微小残留疾病（MRD）检测策略，以反映疾病生物学和可用的治疗方案。最后，最终用户——学术机构、生物製药公司、诊断实验室和医院——各自有着独特的需求。学术中心优先考虑方法创新和转化研究，生物製药公司重视用于临床试验的标准化检测，诊断实验室重视检测通量和成本效益，而医院则优先考虑週转时间和与电子健康记录的整合。了解这些相互依存关係，可以更精确地协调产品设计、临床证据产生和商业模式。

区域战略情报地图绘製：美洲、中东和非洲以及亚太地区的采用趋势、基础设施优势、报销动态和合作生态系统

区域动态对微小残留病灶（MRD）的部署有显着影响，因为不同地区的监管系统、报销框架和实验室基础设施差异巨大。在美洲，高密度的成熟参考实验室和临床试验支持新型MRD平台的快速普及，但支付方覆盖范围的差异可能会限制其在临床试验之外的常规应用。该地区的诊断网络也发挥创新中心的作用，吸引临床中心和产业界的伙伴关係，从而加速实证医学证据的产生和应用。

欧洲、中东和非洲的异质性显而易见：西欧市场受益于整合的报销机制和完善的实验室认证体系，而中东和非洲的许多国家则面临检测能力不足的问题，限制了先进微小残留疾病（MRD）检测的普及。联合采购安排和区域参考实验室正逐渐成为弥合这一差距的可行方案。在亚太地区，对本土生产的投资、临床试验活动的活性化以及医院网路的扩张正在推动检测技术的普及，但监管时间表和当地验证要求要求必须制定周密的市场准入计画。综上所述，这些区域模式表明，商业化策略必须因地制宜。一些地区受益于扩充性的集中式检测模式，而其他地区则受益于分散式的照护现场和就近检测方法，这些方法能够更好地满足检测的可及性和灵活性需求。

透过垂直整合伙伴关係关係来塑造竞争地位；各产业关键洞察，聚焦在证据生成与服务差异化策略

当前微生物诊断（MRD）领域的竞争格局呈现出专业化融合与整合并存的趋势。诊断试剂开发商和平台提供者在分析灵敏度、检测稳健性和临床工作流程整合便利性方面展开竞争，而试剂供应商则在一致性、批间可靠性和符合监管规定的供应链方面展开竞争。平台整合商和临床实验室网路正日益提供包含仪器、软体辅助解读和报告范本的捆绑式服务，以满足临床医生的决策需求。

诊断公司与生物製药赞助商之间的合作能够共同开发用于治疗计画的伴随微小残留疾病（MRD）检测，而与学术中心的合作则可提供检验队列和真实世界证据。与此同时，一些公司正在寻求垂直整合——将检测开发、生产和临床服务交付整合到一个平台——以降低供应风险并获得更大的下游价值。服务差异化不仅体现在分析效能上，也体现在培训、认证支援和上市后监测能力。透过同侪审查的证据证明其临床效用的能力，日益成为市场领导者与利基市场参与者之间的分水岭。这种竞争态势表明市场正在成熟，与临床相关人员的策略合作以及卓越的营运将决定长期的成功。

为行业领导者提供切实可行的、优先排序的建议，以降低风险，并协调临床证据运作和支付方参与，从而加速应用。

致力于加速微小残留病灶（MRD）应用的行业领导者应采取一系列务实倡议，将临床效用与营运可行性相结合。首先，应优先产生可靠的临床证据，将MRD终点纳入前瞻性治疗试验，并进行真实世界结果研究，以展示MRD指导的决策如何改变患者的治疗轨迹。其次，应透过寻找替代供应商、建立区域库存缓衝以及考虑在本地生产高风险组件来增强供应链韧性，从而降低关税和物流风险。

第三，儘早与支付者接洽，确保临床效益体现在报销路径中，采用成本效益模型和与临床适应症相关的分级覆盖策略。第四，投资建造可互通的数位基础设施，将实验室检测结果与电子健康记录和决策支援工具连接起来，以减少临床医生的工作阻力，并确保及时协调医疗服务。第五，采用灵活的商业模式，例如基于绩效的定价和分级服务，以降低资源受限环境下的应用门槛。最后，重视人才队伍建设，透过标准化的培训和认证项目，确保分散式侦测环境中侦测效能的一致性。综上所述，这些措施将有助于在快速发展的诊断环境中，平衡长期策略定位与当前的业务需求。

一项透明的调查方法，描述了用于深入了解微小残留疾病检测的资料来源、专家参与、分析框架和检验方法。

本分析综合了来自多方面研究途径的证据，旨在对研究结果进行三角验证并减少偏差。调查方法结合了对同行评审文献、临床指南、监管文件和技术白皮书的系统性回顾，以及有针对性的初步研究，包括对临床专家、首席研究员、生物製药研发负责人和供应链专业人员的访谈。在条件允许的情况下，将检测性能数据与已发表的验证研究和监管摘要进行比较，以评估其一致性和可重复性。

分析架构包括技术成熟度评估、价值链映射和相关人员影响分析，旨在了解瓶颈和机会的交会点。透过情境分析，对区域政策和关税的影响进行定性建模，并考虑了采购路径、前置作业时间敏感度和区域製造的可行性。研究结果透过专家评审会议进行迭代检验，以协调不同的观点并突出其局限性。主要调查方法的局限性包括已发布的测试方法文件存在差异、监管指南不断变化以及未来政策调整存在固有的不确定性。在製定结论和建议时，已明确考虑了这些因素。

总结结论，重点阐述将决定微小残留病灶诊断未来发展轨迹的机会、营运挑战和策略重点。

摘要：微小残留疾病（MRD）检测正处于关键的十字路口，分析技术的进步、临床检验工作和商业性策略正在融合，以实现更广泛的临床效用。目前可用的诊断方法提供了一套套件，能够适应疾病生物学和医疗服务提供方面的限制，但成功的规模化应用将取决于严谨的证据生成、稳健的供应链以及支付方的积极参与。诸如关税和不断变化的报销制度等政策变化增加了复杂性，需要进行适应性的商业化和营运规划。

对于整个生态系中的相关人员，协作是未来发展的关键。临床和实验室机构必须就标准化操作流程达成一致，业界必须投资于可重复的检测设计和证据，支付方和监管机构必须与申办方合作，制定将微小残留病灶（MRD）检测结果转化为有意义的临床决策的路径。落实这些优先事项将决定MRD能否成为精准肿瘤学中的常规工具，还是仍只能作为一种特殊应用。技术能力与系统层面的准备程度之间的平衡最终将影响患者的治疗机会和治疗创新。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 液态切片技术在非侵入性残留病灶监测的应用日益广泛
  • 数位PCR技术的进步提高了疾病检测的敏感度。
  • 增加对微小残留病灶研究的投入，以支持早期治疗性介入策略
  • 制定实验室间微小残留病灶评估的标准化通讯协定
  • 整合人工智慧工具以提高微小残留病灶资料的准确性和解读能力
  • 微小残留病灶状态作为骨髓恶性肿瘤预后生物标记的应用日益广泛
  • 液态切片技术在微量残存疾病的非侵入性监测中快速应用
  • 重点关注成本效益和可近性，以促进医疗保健系统中微量残存疾病检测的广泛应用。
  • 诊断公司与生物製药公司在伴随 MRD 检测开发的合作
  • 扩大微量残存疾病检测在个人化癌症治疗的应用

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 依检测类型分類的微量残存疾病检测市场

  • 细胞遗传学
    • 染色体微阵列
    • 萤光杂合反应萤光（FISH）
  • 流式细胞技术
    • 多参数流式细胞技术
    • 单参数流式细胞技术
  • 次世代定序仪（NGS）
    • 标靶定序
    • 全基因组定序
  • 聚合酵素链锁反应（PCR）
    • 数位PCR
    • 定量PCR

第九章 依应用分類的微量残存疾病检测市场

  • 白血病
    • 急性淋巴性白血病（ALL）
    • 急性骨髓性白血病（AML）
    • 慢性淋巴性白血病（CLL）
  • 淋巴瘤
    • 何杰金氏淋巴瘤
    • 非何杰金氏淋巴瘤
  • 多发性骨髓瘤
  • 固体癌
    • 乳癌
    • 大肠直肠癌

第十章 产业微量残存疾病检测市场

  • 学术和研究机构
  • 生物製药公司
  • 诊断实验室
  • 医院

第十一章 区域性微量残存疾病检测市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 按组别分類的微量残存疾病检测市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 各国微量残存疾病检测市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Agilus Diagnostics Ltd.
    • Amgen Inc.
    • Adaptive Biotechnologies Corporation
    • ARUP Laboratories
    • AstraZeneca PLC
    • Asuragen Inc. by Bio-Techne Corporation
    • Bio-Rad Laboratories, Inc.
    • Bristol-Myers Squibb Company
    • C2I Genomics Inc.
    • Cergentis BV
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • Genetron Holdings Limited
    • GRAIL, LLC by Illumina, Inc.
    • Guardant Health, Inc.
    • Integrated DNA Technologies, Inc.
    • Invivoscribe, Inc.
    • Kite Pharma, Inc. by Gilead Sciences, Inc.
    • Laboratory Corporation of America Holdings
    • Mdxhealth BV
    • MedGenome Inc
    • Mission Bio, Inc.
    • Myriad Genetics, Inc.
    • Natera Inc.
    • NeoGenomics Laboratories, Inc.
    • OPKO Health, Inc.
    • Quest Diagnostics incorporated
    • Sysmex Corporation
    • Veracyte, Inc.
Product Code: MRR-961BA04A2E6C

The Minimal Residual Disease Testing Market is projected to grow by USD 4.47 billion at a CAGR of 11.47% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 1.87 billion
Estimated Year [2025] USD 2.08 billion
Forecast Year [2032] USD 4.47 billion
CAGR (%) 11.47%

Minimal residual disease (MRD) testing has evolved from a specialized research assay into a pivotal clinical tool that informs prognosis, guides therapeutic intensity, and enables adaptive treatment strategies across hematologic and selected solid tumor indications. Clinicians and laboratory leaders now view MRD not merely as a biomarker but as a decision-making instrument that affects remission assessment, relapse surveillance, and eligibility for novel therapies. Consequently, the diagnostic landscape is responding with a broader array of analytical approaches, enhanced sensitivity thresholds, and workflows designed to integrate results into fast-moving clinical pathways.

The introduction of more sensitive platforms and the alignment of clinical trial endpoints with MRD status have accelerated clinical adoption, while parallel advances in sample handling, quality control, and reporting standards are beginning to reduce variability across testing sites. As a result, MRD testing occupies an intersection of clinical urgency and technological innovation: it must deliver reproducible, clinically actionable results within timelines that influence therapeutic choices. Understanding the interplay between analytical capability, clinical validation, and operational readiness is therefore essential for stakeholders seeking to scale MRD testing from specialized centers to routine care settings.

Transformative shifts redefining minimal residual disease testing driven by analytical innovation clinical validation and integration into therapeutic decision frameworks

The MRD landscape is undergoing transformative shifts driven by convergence between high-sensitivity molecular techniques, refined cellular assays, and digital analytics. Innovations such as targeted next-generation sequencing panels tailored for low-allele-frequency detection, digital PCR approaches that deliver absolute quantitation, and multi-parameter flow cytometry optimized for standardized immunophenotyping are collectively raising the floor of detectability. Concurrently, improvements in sample preservation, centralized reference testing, and cross-platform validation studies are reducing inter-laboratory variance and increasing clinician confidence in MRD readouts.

Beyond raw analytical progress, the integration of MRD into clinical trial design and regulatory pathways is reshaping commercial and clinical incentives. As MRD is increasingly used as an early surrogate endpoint for therapeutic efficacy, sponsors are structuring trials and regulatory engagements to demonstrate how MRD-informed dosing or duration strategies improve patient outcomes. Additionally, digital infrastructure-ranging from laboratory information systems to cloud-based variant interpretation-supports faster result delivery and federated analytics, which in turn enable scalable clinical decision support. Together, these shifts are accelerating MRD from a niche diagnostic towards a standardized element of precision oncology workflows.

Assessing the cumulative effects of United States tariff policy adjustments in 2025 on supply chains cost structures and clinical access to minimal residual disease diagnostics

Tariff changes enacted in 2025 have introduced a new layer of operational complexity for stakeholders that depend on a globally integrated supply chain for instruments, reagents, and consumables. Increased duties on imported specialized equipment and assay components raise unit costs and create incentive pressures to adjust procurement strategies. For clinical laboratories and diagnostic manufacturers, these cost pressures can translate into tighter margins, delayed capital renewal cycles for high-cost instrumentation, and a need to reassess pricing or service models to maintain viability without compromising clinical access.

In addition to direct cost effects, tariffs contribute to supply chain friction that can lengthen lead times for critical reagents and spare parts. Extended replenishment cycles exacerbate inventory risk for high-throughput centers and may compel laboratories to diversify supplier portfolios or to qualify alternative assay formats that rely on locally sourced inputs. Policy responses and commercial mitigations have begun to emerge: some organizations are accelerating regional manufacturing investments, while others are negotiating long-term supply agreements that allocate tariff risk. Clinically, the net effect is uneven; well-resourced systems can absorb short-term disruption through internal buffering and strategic procurement, whereas resource-constrained hospitals and diagnostic networks may face delays or restricted access to advanced MRD platforms. Consequently, stakeholders must factor in tariff-induced cost and availability shifts when projecting technology adoption timelines and when designing resilient operational models.

Key segmentation insights demonstrating how test modalities clinical applications and end-user verticals combine to determine adoption priorities and value creation

A segmentation-aware perspective reveals how analytical modality, clinical indication, and end-user type interact to shape adoption pathways and value creation for MRD testing. Test types such as cytogenetics with chromosomal microarray and FISH retain critical roles for structural aberration detection in certain hematologic contexts, but they coexist with flow cytometry approaches where multi-parameter and single-parameter platforms offer complementary cellular resolution. Molecular modalities occupy a central position: targeted next-generation sequencing panels and whole-genome sequencing provide sensitivity and breadth for mutation-based MRD assessment, while digital PCR and quantitative PCR deliver rapid, cost-efficient quantitation for predefined targets.

Application areas further guide which technical profile is prioritized. In leukemia subtypes including acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia, both molecular and immunophenotypic assays are used to provide orthogonal confirmation of remission status. Lymphoma testing, encompassing Hodgkin's and non-Hodgkin's variants, requires tailored assay designs that balance sensitivity against tumor heterogeneity. Multiple myeloma and selected solid tumors such as breast and colorectal cancer demand bespoke MRD strategies that reflect disease biology and available therapeutic options. Finally, end-user verticals-academic and research institutes, biopharmaceutical companies, diagnostic laboratories, and hospitals-each press unique requirements. Academic centers prioritize methodological innovation and translational research, biopharmaceutical sponsors emphasize standardized assays for clinical trials, diagnostic laboratories focus on throughput and cost-efficiency, and hospitals prioritize turnaround time and integration with electronic medical records. Understanding these interdependencies enables more precise alignment of product design, clinical evidence generation, and commercial models.

Regional strategic intelligence mapping adoption trends infrastructure strengths reimbursement dynamics and collaborative ecosystems across the Americas Europe Middle East & Africa and Asia-Pacific

Regional dynamics exert a strong influence on MRD deployment because regulatory regimes, reimbursement frameworks, and laboratory infrastructure diverge significantly across geographies. In the Americas, established reference laboratories and a high density of clinical trials support relatively rapid uptake of novel MRD platforms, although payer coverage variability can constrain routine use outside of trial settings. The region's diagnostic networks also serve as hubs for innovation, attracting partnerships between clinical centers and industry that accelerate evidence generation and adoption.

Across Europe, the Middle East & Africa, heterogeneity is pronounced: Western European markets benefit from consolidated reimbursement pathways and robust laboratory accreditation systems, while many countries in the Middle East and Africa face capacity constraints that limit access to advanced MRD testing. Collaborative procurement mechanisms and regional reference laboratories are emerging as pragmatic solutions to bridge gaps. In the Asia-Pacific, investment in domestic manufacturing, rising clinical trial activity, and expanding hospital networks are driving uptake, though regulatory timelines and local validation requirements necessitate careful market entry planning. Collectively, these regional patterns imply that commercialization strategies must be tailored: scalable centralized testing models may work in some geographies, whereas decentralized point-of-care or near-patient approaches could better address access and timeliness in others.

Key company-level insights highlighting partnerships vertical integration evidence generation and service differentiation strategies that shape competitive positioning

Contemporary competitive dynamics in the MRD space are characterized by a blend of specialization and integration. Diagnostic developers and platform providers differentiate through analytical sensitivity, assay robustness, and ease of clinical workflow integration, while reagent suppliers compete on consistency, lot-to-lot reliability, and regulatory-compliant supply chains. Platform integrators and clinical laboratory networks are increasingly offering bundled services that combine instrumentation, software-enabled interpretation, and reporting templates that align with clinician decision needs.

Partnership models stand out as an accelerant: collaborations between diagnostic firms and biopharmaceutical sponsors enable co-development of companion MRD assays for therapeutic programs, while alliances with academic centers provide validation cohorts and real-world evidence. In parallel, some organizations are pursuing vertical integration-bringing assay development, manufacturing, and clinical service delivery under one operational umbrella-to reduce supply risk and capture greater downstream value. Service differentiation extends beyond analytical performance to include training, accreditation support, and post-market surveillance capabilities; the ability to demonstrate clinical utility through peer-reviewed evidence increasingly separates market leaders from niche players. These competitive behaviors suggest a maturing market where strategic alignment with clinical stakeholders and operational excellence determine long-term success.

Actionable and prioritized recommendations for industry leaders to accelerate adoption mitigate risk and align clinical evidence operational execution and payer engagement

Industry leaders seeking to accelerate MRD adoption should pursue a pragmatic set of actions that align clinical utility with operational feasibility. First, prioritize robust clinical evidence generation by embedding MRD endpoints into prospective therapeutic trials and by conducting real-world outcome studies that demonstrate how MRD-guided decisions alter patient trajectories. Second, strengthen supply chain resilience by qualifying alternative suppliers, building regional inventory buffers, and exploring localized production for high-risk components to mitigate tariff and logistics exposures.

Third, engage payers early to translate clinical benefit into reimbursement pathways, using cost-effectiveness models and phased coverage strategies tied to clinical indications. Fourth, invest in interoperable digital infrastructure that links laboratory results with electronic medical records and decision-support tools, thereby reducing clinician friction and ensuring timely therapeutic adjustments. Fifth, adopt flexible commercial models such as performance-based pricing or tiered service offerings to lower barriers for adoption in resource-constrained settings. Lastly, commit to workforce development through standardized training and accreditation programs that ensure consistent assay performance across decentralized testing environments. Collectively, these actions balance immediate operational needs with longer-term strategic positioning in a rapidly evolving diagnostic landscape.

Transparent research methodology explaining data sources expert engagements analytical frameworks and validation approaches used to derive insights on minimal residual disease testing

This analysis synthesizes evidence from a multi-pronged research approach designed to triangulate findings and reduce bias. The methodology combined systematic review of peer-reviewed literature, clinical guidelines, regulatory documents, and technical white papers with targeted primary research comprising interviews with clinical experts, laboratory directors, biopharma development leads, and supply chain specialists. Where available, assay performance data was compared across published validation studies and regulatory summaries to assess concordance and reproducibility.

Analytical frameworks included technology readiness assessment, value-chain mapping, and stakeholder impact analysis to understand where bottlenecks and opportunities converge. Regional policy and tariff impacts were modeled qualitatively through scenario analysis that considered procurement pathways, lead-time sensitivity, and the feasibility of regional manufacturing. Findings were iteratively validated through expert review sessions to reconcile divergent perspectives and to highlight limitations. Key methodological limitations include variability in published assay documentation, evolving regulatory guidance, and the inherent uncertainty around future policy adjustments; these factors were explicitly considered when framing conclusions and recommendations.

Concluding synthesis emphasizing the opportunities operational challenges and strategic priorities that will determine the future trajectory of minimal residual disease diagnostics

In summary, MRD testing stands at a pivotal juncture where analytical advances, clinical validation efforts, and commercial strategies converge to enable broader clinical utility. The diagnostic modalities available today collectively offer a toolkit that can be matched to disease biology and care delivery constraints, but successful scale-up depends on rigorous evidence generation, resilient supply chains, and payer engagement. Policy shifts such as tariffs and evolving reimbursement landscapes add complexity, requiring adaptive commercialization and operational planning.

For stakeholders across the ecosystem, the path forward centers on collaboration: clinical sites and laboratories must align on standardized practices, industry must invest in reproducible assay design and evidence, and payers and regulators should work with sponsors to define pathways that translate MRD detection into meaningful clinical decisions. Executing on these priorities will determine whether MRD fulfills its promise as a routine instrument of precision oncology or remains confined to specialized use cases. The balance of technical capability and system-level readiness will ultimately shape patient access and therapeutic innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of liquid biopsy techniques for non-invasive residual disease monitoring
  • 5.2. Advancements in digital PCR technology enhancing sensitivity of disease detection
  • 5.3. Rising investment in research focusing on minimal residual disease to support early treatment intervention strategies
  • 5.4. Development of standardized protocols for minimal residual disease assessment across laboratories
  • 5.5. Integration of artificial intelligence tools to improve accuracy and interpretation of minimal residual disease data
  • 5.6. Increasing use of MRD status as a prognostic biomarker in hematologic malignancies
  • 5.7. Rapid growth in the adoption of liquid biopsy techniques for non-invasive monitoring of minimal residual disease
  • 5.8. Focus on cost-effectiveness and accessibility to broaden the reach of minimal residual disease testing in healthcare systems
  • 5.9. Collaborations between diagnostic firms and biopharma to develop companion MRD tests
  • 5.10. Expanding applications of minimal residual disease testing in personalized cancer therapies

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minimal Residual Disease Testing Market, by Test Type

  • 8.1. Cytogenetics
    • 8.1.1. Chromosomal microarray
    • 8.1.2. Fluorescence in situ hybridization (FISH)
  • 8.2. Flow Cytometry
    • 8.2.1. Multi-parameter flow cytometry
    • 8.2.2. Single-parameter flow cytometry
  • 8.3. Next-Generation Sequencing (NGS)
    • 8.3.1. Targeted sequencing
    • 8.3.2. Whole genome sequencing
  • 8.4. Polymerase Chain Reaction (PCR)
    • 8.4.1. Digital PCR
    • 8.4.2. Quantitative PCR

9. Minimal Residual Disease Testing Market, by Application Areas

  • 9.1. Leukemia
    • 9.1.1. Acute Lymphoblastic Leukemia (ALL)
    • 9.1.2. Acute Myeloid Leukemia (AML)
    • 9.1.3. Chronic Lymphocytic Leukemia (CLL)
  • 9.2. Lymphoma
    • 9.2.1. Hodgkin's lymphoma
    • 9.2.2. Non-Hodgkin's lymphoma
  • 9.3. Multiple Myeloma
  • 9.4. Solid Tumors
    • 9.4.1. Breast cancer
    • 9.4.2. Colorectal cancer

10. Minimal Residual Disease Testing Market, by End-User Vertical

  • 10.1. Academic & Research Institutes
  • 10.2. Biopharmaceutical Companies
  • 10.3. Diagnostic Laboratories
  • 10.4. Hospitals

11. Minimal Residual Disease Testing Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Minimal Residual Disease Testing Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Minimal Residual Disease Testing Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. Agilus Diagnostics Ltd.
    • 14.3.2. Amgen Inc.
    • 14.3.3. Adaptive Biotechnologies Corporation
    • 14.3.4. ARUP Laboratories
    • 14.3.5. AstraZeneca PLC
    • 14.3.6. Asuragen Inc. by Bio-Techne Corporation
    • 14.3.7. Bio-Rad Laboratories, Inc.
    • 14.3.8. Bristol-Myers Squibb Company
    • 14.3.9. C2I Genomics Inc.
    • 14.3.10. Cergentis B.V.
    • 14.3.11. Exact Sciences Corporation
    • 14.3.12. F. Hoffmann-La Roche Ltd.
    • 14.3.13. Genetron Holdings Limited
    • 14.3.14. GRAIL, LLC by Illumina, Inc.
    • 14.3.15. Guardant Health, Inc.
    • 14.3.16. Integrated DNA Technologies, Inc.
    • 14.3.17. Invivoscribe, Inc.
    • 14.3.18. Kite Pharma, Inc. by Gilead Sciences, Inc.
    • 14.3.19. Laboratory Corporation of America Holdings
    • 14.3.20. Mdxhealth BV
    • 14.3.21. MedGenome Inc
    • 14.3.22. Mission Bio, Inc.
    • 14.3.23. Myriad Genetics, Inc.
    • 14.3.24. Natera Inc.
    • 14.3.25. NeoGenomics Laboratories, Inc.
    • 14.3.26. OPKO Health, Inc.
    • 14.3.27. Quest Diagnostics incorporated
    • 14.3.28. Sysmex Corporation
    • 14.3.29. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)

TABLE 2